The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.

Trial Details

NCT ID
NCT06911710
Phase
PHASE1 / PHASE2
Sponsor
Tianjin Medical University General Hospital
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • With their own consent and have signed an informed consent form, willing and able to comply with the planned visits, study treatment, laboratory te…
  • Subjects in the different cohorts will still be required to fulfill the following conditions:
  • Lymphoma Cohort:
  • B-cell lymphoma Diagnosis of CD19+ and/or CD20+ and/or CD22+ and/or BAFF+ B-cell lymphoma confirmed by pathology and histology; Inert B-cell lympho…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →